AI
ALNY icon

Atria Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History

Atria Investments’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.01M Sell
6,676
-3,198
-32% -$965K 0.02% 751
2026
Q1 		$3.27M Buy
9,874
+3,701
+60% +$1.26M 0.04% 514
2025
Q4 		$2.45M Buy
6,173
+979
+19% +$433K 0.03% 638
2025
Q3 		$2.37M Buy
5,194
+918
+21% +$374K 0.03% 659
2025
Q2 		$1.39M Buy
4,276
+72
+2% +$19.9K 0.02% 886
2025
Q1 		$1.14M Buy
4,204
+893
+27% +$229K 0.01% 946
2024
Q4 		$779K Buy
3,311
+166
+5% +$43.7K 0.01% 1118
2024
Q3 		$865K Buy
3,145
+1,387
+79% +$361K 0.01% 1049
2024
Q2 		$427K Buy
+1,758
New +$278K 0.01% 1383

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Atria Investments's ALNY Position: Q2 2026 in Review

Atria Investments reduced its Alnylam Pharmaceuticals (ALNY) stake by 32% in Q2 2026, selling an estimated $965K and leaving 6,676 shares worth $2.01M. The position accounts for 0.02% of the portfolio, ranked #751.

Atria Investments first reported a position in ALNY in Q2 2024 and has held it in 9 quarters since. The position peaked at $3.27M in Q1 2026. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Atria Investments held 6,676 shares of Alnylam Pharmaceuticals worth $2.01M as of Q2 2026.
  • Atria Investments sold 3,198 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $965K.
  • Alnylam Pharmaceuticals made up 0.02% of Atria Investments's portfolio in Q2 2026, its #751 holding.
  • Atria Investments first reported a position in Alnylam Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Atria Investments's Alnylam Pharmaceuticals position peaked at $3.27M in Q1 2026.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Atria Investments's 13F filing for Q2 2026, filed 28 Jul 2026.